Since its introduction as an alternative intestinal microbiota alteration approach, fecal microbiota transplantation (FMT) has been increasingly used as a treatment of choice for patients with ulcerative colitis (UC), but no reports exist regarding FMT via percutaneous endoscopic cecostomy (PEC). This report describes the case of a 24-year-old man with a 7-year history of recurrent, steroid-dep...

ABST RACT This case report describes a 10-year-old, 2.9 kg, female spayed Abyssinian cat diagnosed with ulcerative colitis (UC), unresponsive to conventional therapy. A fecal microbiota transplantation (FMT) through rectal (enema) administration was performed as a last therapeutic option for the cat before euthanasia, and there was an immediate improvement after the procedure in regards to feca...

Fecal microbiota transplantation (FMT) has had a long history in medicine for treating a number of human diseases. As early as during the 4 century BC, FMT was used in China to treat patients with food poisoning and diarrhea. Over time, the method became obsolete, particularly after the realization that hygiene plays an important role in preventing infectious diseases. It was not until the late...

R ecurrent Clostridium difficile infection (CDI) exhibits a disrupted diverse gut microbiome where recolonization decides the final outcome of this often challenging course of disease. Clinical trial and error treatment with fecal microbiota transplant (FMT) have until recently produced limited amount of scientific data. Lack of a standardized procedure and obscure declaration of product conten...

Irritable bowel syndrome is a disorder of the gastrointestinal tract with unknown etiology. Recent clinical data support a link between changes in fecal microbiota with decreased biodiversity and the development of irritable bowel syndrome. Whether these changes of the microbiota are caused by the disease or whether they develop during the course of the disease remains unclear. Several studies ...

BACKGROUND Faecal microbiota transplantation or transfer (FMT) aims at replacing or reinforcing the gut microbiota of a patient with the microbiota from a healthy donor. Not many controlled or randomised studies have been published evaluating the use of FMT for other diseases than Clostridium difficile infection, making it difficult for clinicians to decide on a suitable indication. AIM To pr...

Fecal microbiota transplantation (FMT) has evolved from a case report in the medical literature to the basis of major innovations in the treatment of Clostridium difficile infection (CDI) and, potentially, inflammatory bowel disease (IBD). In the clinical setting, FMT was noted to significantly lower the risk of recurrent CDI, likely by increasing microbial diversity and altering the metabolic ...

BACKGROUND Faecal microbial transplant (FMT) for recurrent Clostridium difficile infection (rCDI) is greatly facilitated by frozen stool banks. However, the effect of frozen storage of stool for greater than 2 months on the viability of stool bacteria is unknown and the efficacy of FMT is not clear. AIM To evaluate the viability of bacteria in stool frozen for up to 6 months, and the clinical...

While fecal microbiota transplantation (FMT) presents an attractive therapeutic strategy, it remains unclear how to choose the microbiota repertoire that most effectively transfers benefit to recipients. We identified a beneficial taxonomic repertoire in a transgenic mouse model (RIP140mϕKD) which resists the development of high fat diet (HFD)-induced metabolic diseases due to enhanced anti-inf...